Autologous chimeric antigen receptor (CAR) T cells have changed the therapeutic
landscape in haematological malignancies. Nevertheless, the use of allogeneic CAR T cells …

Because of their potent antitumor activity and their proinflammatory role, natural killer (NK)
cells are at the forefront of efforts to develop immuno-oncologic treatments. NK cells …

Immunosenescence is a process of immune dysfunction that occurs with age and includes
remodeling of lymphoid organs, leading to changes in the immune function of the elderly …

CD123, the alpha chain of the IL-3 receptor, is an attractive target for acute myeloid
leukemia (AML) treatment. However, cytotoxic antibodies or T cell engagers targeting …

Immuno-oncology is an emerging field that has revolutionized cancer treatment. Most
immunomodulatory strategies focus on enhancing T cell responses, but there has been a …

Natural killer (NK) cells provide protection against infectious pathogens and cancer. For
decades it has been appreciated that two major NK cell subsets (CD56 bright and CD56 …

Over the last decade, various new therapies have been developed to promote anti-tumor
immunity. Despite interesting clinical results in hematological malignancies, the …

In spite of the recent approval of new promising targeted therapies, the clinical outcome of
patients with acute myeloid leukemia (AML) remains suboptimal, prompting the search for …

The past several years have seen tremendous advances in the engineering of immune
effector cells as therapy for cancer. While chimeric antigen receptors (CARs) have been …

The contribution of natural killer (NK) cells to immunosurveillance of human cancer remains
debatable. Here, we discuss advances in several areas of human NK cell research, many of …